- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01510418
Socialization of Adult Men With Congenital Hemophilia A or B (PWBCD)
Socialization of Adult Men With Congenital Hemophilia A or B: A Study to Examine Socialization Measures, the Role of Spouse/Significant Other and Health Related Quality of Life
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
There are two groups (cohorts) in this study. One group is adult men with congenital hemophilia A or B who qualify for the study. The other group is their spouse or significant other (SSO) who are voluntarily identified by the person with congenital bleeding disorder for recruitment into the study.
For the adult men with congenital hemophilia A or B, the study involves a minimum of 2 visits and includes screening, medical history and physical exam review, completing confidential questionnaires and interview.
Eligible men with congenital hemophilia A or B (person with congenital bleeding disorder, PWCBD) are given the option to permit the investigator to contact their spouse or significant other (SSO) for participation in the study. If PWCBD has an SSO, the SSO is not required to participate in the study.
Spouse/significant other(SSO)of men with congenital hemophilia A or B may enter the study only if they have been voluntarily identified by their partner (PWCBD) and their partner has opted to allow investigator to contact them. For the SSO who chooses to participate in the study, the study will involve a minimum of one visit and includes completing confidential questionnaires and interview.
All participation including questionnaires and interview information collected is confidential and protected by health privacy information laws and records are de-identified.
The study is sponsored by a grant from The National Hemophilia Foundation.
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02215
- Dana-Farber Cancer Institute
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
There are two study populations:
PWCBD: Person with congenital bleeding disorders are adult men with congenital hemophilia A or B who receive care in Massachusetts or who reside in the New England area or elsewhere and are willing to travel to the study site may be eligible for recruitment.
Beskrivning
Eligibility criteria for person with congenital bleeding disorder(PWCBD, men with congenital hemophilia):
- Known diagnosis of congenital hemophilia A or B with or without inhibitor (defined by a plasma factor VIII or factor IX level below lower limits of normal and medical history consistent with diagnosis).
- Male age 21 years or older
- Willing to indicate if they have a spouse or significant other.
- Able to read, write and participate in interview on site.
Exclusion Criteria for PWCBD:
- Other bleeding disorder besides congenital hemophilia A or B
Eligibility criteria for spouses/significant other (SSO) participants in the study:
- A person in a relationship for a minimum of 9 months with the PWCBD participating in the study.
- PWCBD partner must be participating in the study.
- Willing to participate in questionnaire and interview on site.
Exclusion criteria for SSO:
- Biologically related to PWCBD participant (that is, not a parent, sibling, child or other biologically-related caregiver).
Studieplan
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
---|
Person with congenital bleeding disorder
Adult men with congenital hemophilia A or B
|
Spouse/Significant Other
Spouse/significant other of person with congenital bleeding disorder participating in this study.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Health related quality of life, description of support and networks.
Tidsram: 2 years
|
Standard health-related quality of life questionnaires and interview are used to obtain primary outcome measure about PWCBD.
|
2 years
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Quality of life and description of role of SSO in health care of their PWCBD partner
Tidsram: 2 years
|
Standardized quality of life questionnaire, social-medical questionnaire and interview of SSO are used to obtain this outcome measure.
|
2 years
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Aric Parnes, MD, Brigham and Women's Hospital
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 10-343
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Blödarsjuka A
-
King Saud UniversityAvslutad
-
Cheikh Anta Diop University, SenegalInternational Atomic Energy AgencyHar inte rekryterat ännu
-
National Institute of Environmental Health Sciences...IndragenBisfenol A
-
Medical University of ViennaAvslutad
-
Ionis Pharmaceuticals, Inc.AvslutadFörhöjt lipoprotein(a)Nederländerna, Storbritannien, Danmark, Tyskland, Kanada
-
Ionis Pharmaceuticals, Inc.Akcea TherapeuticsAvslutad
-
University of California, DavisBill and Melinda Gates Foundation; Penn State University; Newcastle University och andra samarbetspartnersAvslutadVitamin A-statusFilippinerna
-
Arab American University (Palestine)AvslutadA-PRF | ALLOGRAFTPalestinska territoriet, ockuperat
-
AmgenAvslutad
-
Shanghai Jiao Tong University School of MedicineAvslutadBotulinumtoxin, typ A